Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TOP2A | P11388 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764476 | 1.00 | EP300 (0.52) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL28886289 | 0.92 | MAPT (0.46) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL22099937 | 0.92 | MAPT (0.46) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL20764525 | 0.90 | EP300 (0.52) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL20764523 | 0.90 | EP300 (0.52) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL20764473 | 0.85 | MEN1 (0.37) | EP300TP53MDM2HDAC1HDAC3 | |
| SCHEMBL20764477 | 0.85 | MEN1 (0.37) | EP300TP53MDM2HDAC1HDAC3 | |
| SCHEMBL28885632 | 0.84 | EP300 (0.45) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL20764592 | 0.82 | SMN1; SMN2 (0.37) | EP300TP53MDM2HDAC1HDAC3 | |
| SCHEMBL17775429 | 0.81 | EP300 (0.69) | EP300BCL2BCL2L1MCL1BAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| EP-3672937-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| WO-2019038405-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | EP300 3960/4885BCL2 1552/4885BCL2L1 1590/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | EP300 4224/4885BCL2 1788/4885BCL2L1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.